← Back to headlines
FDA Accepts Bristol Myers Squibb's NDA for Iberdomide with Priority Review
The FDA has accepted Bristol Myers Squibb's New Drug Application (NDA) for Iberdomide, granting it Priority Review status. This indicates the agency's expedited review of the drug.
24 Feb, 07:11 — 24 Feb, 07:11
ℹOnly 1 source covers this story
